Consistently, Naso et al. demonstrated that PINK1/Parkin-dependent mitophagy could be activated in response to doxorubicin treatment in breast cancer and that mitophagy inhibition through miR-218-5p expression enhances the sensitivity of breast cancer cells to doxorubicin [147]. Here, PRKN is linked to breast carcinoma.